RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viability, in a new U.S. Army-funded and conducted in vitro Ebola virus study
Related news for (RDHL)
- Bitcoin, Biotech, and Biosteel: Innovation Powers the Opening Bell
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/29/25 08:00 AM
- Breaking News: MoBot’s Latest Update as of 09/29/25 07:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/21/25 01:00 PM
- Top Biotech Movers: Transformative Breakthroughs Fuel Investor Interest Across Neurology, Autoimmunity, and Advanced Materials
